Beyond Meat Earnings Call Transcripts
Fiscal Year 2025
-
Q4 2025 saw a 19.7% revenue decline and a net income boost from debt restructuring, amid weak demand and major non-routine charges. The company is pivoting to adjacent categories, launching a new beverage line, and focusing on cost control and operational efficiency.
-
Stockholders approved four key proposals, including new convertible notes, equity plan expansion, a major increase in authorized shares, and a reverse stock split. Management addressed questions on the reverse split and reaffirmed strategic commitment.
-
Q3 2025 saw a 13% revenue decline and a net loss of $110.7 million, with gross margin dropping to 10.3%. Major debt reduction and new capital raised have reset the balance sheet, while the company focuses on operational efficiency, margin recovery, and product innovation.
-
Q2 2025 net revenue fell 20% year-over-year to $75M, with gross margin down to 11.5% and a net loss of $33.2M. Management is accelerating cost reductions, restructuring operations, and focusing on margin expansion, while guiding Q3 revenue to $68–$73M amid ongoing category softness.
-
The meeting covered director elections, auditor ratification, and executive compensation approval. Management addressed shareholder questions on compensation, product marketing, sustainability, and new product ideas, reaffirming a commitment to transparency and innovation.
-
Q1 2025 saw a 9.1% revenue decline and negative gross margin, driven by U.S. distribution gaps and weak demand. Management withdrew full-year guidance, focusing on cost control, margin recovery, and new financing to support a path to EBITDA positive by end of 2026.
Fiscal Year 2024
-
Year-over-year net revenue growth returned in the second half of 2024, with Q4 revenues up 4% and significant cost reductions driving a nearly $100 million improvement in adjusted EBITDA. 2025 guidance targets flat to modest revenue growth, a 20% gross margin, and further operating expense cuts, with a strategic focus on achieving EBITDA-positive operations by end of 2026.
-
Q3 2024 saw a return to year-over-year revenue growth, gross margin expansion to 17.7%, and significant reductions in operating expenses and net loss. Product innovation and premium positioning drove performance, with positive outlook for continued margin improvement and liquidity actions ahead.
-
Q2 2024 saw net revenues of $93.2M, exceeding guidance but down 8.8% year-over-year, with gross margin rising to 14.7%. Operating expenses and cash use declined sharply, while the Beyond IV product line launch and cost initiatives drove margin gains. Full-year guidance was raised, with further margin improvement expected.